Colorcon chooses the Netherlands for new starch manufacturing plant
The plant will provide a secure second source of supply of Starch 1500, Pregelatinized Maize Starch.
Colorcon is to build a new starch manufacturing plant close to Amsterdam in The Netherlands. By 2022, this new facility is planned to double the existing manufacturing capacity for Starch 1500, Pregelatinized Maize Starch, supporting the continued growth of Colorcon’s excipient business across the world.
Strategically located in the heart of Europe and close to the major port of Rotterdam, the site will produce GMP starch products for the pharmaceutical and nutritional markets served by Colorcon in the EMEA region.
Nathan Evans, Operations Project Manager – Netherlands says: “The location has been chosen to bring manufacturing closer to our customer base in Europe. The plant will provide a secure second source of supply with the same quality, consistency and equivalency to the product manufactured in our existing facility in Indianapolis, IN, USA. The new facility will enable Colorcon to take advantage of new advances in process control and automation to manufacture a product that has over 40 years of history in use across the pharmaceutical industry.”
Martti Hedman, CEO, Colorcon explains the significance of Colorcon’s investment: “By investing ahead of demand, the facility is also an important step in securing the supply chain for our customers and enhances Colorcon’s Business Continuity Plan as the demand for Starch 1500 continues to grow.”
Jayesh Parmar, General Manager adds: “Colorcon is committed to providing the highest quality products and superior service to meet our customers’ needs around the world. This investment reinforces our dedication to providing continuity of supply and highlights our long-term commitment to the specialty excipient business.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.